Work

Is there an additional health-related quality of life (HRQL) benefit with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) beyond that mediated by clinical endpoints?

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.9617

Authors: David Cella, Arturo Molina, Dennis D. Gagnon, Derek Espindle, Yanni Hao, Ethan M. Basch

Institutions: Northwestern University, Janssen Research & Development (United States), Truven Health Analytics (United States), University of North Carolina at Chapel Hill

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602044140

Cites:

Cited by:

Related to: 10